Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

Open Menu
Eine Nahaufname mit Tiefenunschärfe von mehreren, übereinander gelegten Tageszeitungen.

Press release


COVID-19: What is driving the escalating hyperinflammation

Back to Overview

You are here:

Study published in Nature suggests novel treatment option

Blau gefärbte Zellen der Nasenschleimhaut © Charité | Soyoung Lee
Human nasal mucosa cells which have started their senescence program in response to SARS-CoV-2 infection. The cells were stained using the senescence-associated beta-galactosidase assay. This standard test for evaluating senescence produces a characteristic blue color. Photo: Charité | Soyoung Lee

A joint press release by Charité, the MDC, JKU Linz and the Kepler University Hospital

The severity of COVID-19 is not determined solely by the SARS-CoV-2 virus itself; rather, it is the primary result of a dysregulated immune response. A team of researchers from Charité – Universitätsmedizin Berlin, the Max-Delbrück-Center for Molecular Medicine (MDC), Johannes Kepler University (JKU) Linz and Kepler University Hospital (KUK) have identified a cellular stress response mechanism which plays a major role in the derailed immune response: senescence. Senolytic agents – drugs capable of selectively eliminating senescent cells – were shown to mitigate COVID-19-related lung damage in animal models, in addition to significantly reducing inflammation. They may also offer a new treatment path in humans. Results from this study have been published in Nature*.

Cellular senescence is a tissue-protective mechanism which is triggered in response to stress and injury. It results in the programmed cessation of cell division, thereby also protecting against cancer. Senescent cells release pro-inflammatory messengers which are important in wound healing. When present in excess or produced for too long, these inflammation modulators promote age-related diseases like diabetes and atherosclerosis. Sparse evidence that senescence may also be triggered by viral infections has, until now, received little attention. A team of researchers led by the oncologist Prof. Dr. Clemens Schmitt has now shown that this process plays a crucial role in triggering a veritable avalanche of inflammatory mediators, which contribute to the lung damage associated with COVID-19. “In our view, the early use of specific substances which disrupt this inflammatory overreaction holds enormous potential as a new treatment strategy for COVID-19,” says the cancer specialist.

In addition to his position as Director of the Molecular Cancer Research Center (MKFZ), Prof. Schmitt is Head of the MDC’s ‘Cancer Genetics and Cellular Stress Responses’ research group and Research Group Lead at Charité’s Department of Hematology, Oncology and Tumor Immunology on Campus Virchow Klinikum. He is also the Head of Hematology/Oncology at the KUK and holds a professorship at the JKU Linz. Prof. Schmitt´s research into COVID-19 benefits from his long-standing expertise in the field of senescence, in particular as it pertains to cancer. Working alongside his team of researchers, he has been using both cell-based models and animal models to study the role of senescence in the body’s immune response to SARS-CoV-2 infection.

In their article, the researchers show that the cellular stress-response program initiates an avalanche-like inflammatory response which culminates in the pneumonia typically seen in COVID-19. Simply put, the cascade begins inside SARS-CoV-2-infected cells of the upper respiratory tract, where viral entry into mucosal epithelial cells triggers a cellular stress response which activates their senescence program. Once senescent, the mucosal epithelial cells produce ample amounts of pro-inflammatory messengers. These, in turn, attract specific immune cells known as macrophages, which infiltrate the mucosa in order to remove senescent cells. Due to the presence of the pro-inflammatory factors, however, the macrophages are themselves driven into the senescent state and release now large quantities of such factors themselves. Senescent macrophages can then infiltrate the lungs, where they may trigger senescence in other cells, such as the extremely sensitive cells lining the lung’s small blood vessels. Thrombogenic substances produced in response to this insult result in microthrombosis, i.e., the formation of tiny blood clots which obstruct the lung’s small blood vessels. Blood flow and oxygen exchange are severely impaired.

“The cellular stress program is an important driver of such escalating hyperinflammation which plays a major role in producing many of the characteristic features of COVID-19 pneumonia, such as vascular damage and microthrombosis,” explains the study’s first author, Dr. Soyoung Lee, a researcher based at Charité’s Department of Hematology, Oncology and Tumor Immunology on Campus Virchow Klinikum, the MKFZ and the MDC. “It was therefore a logical step to test whether we might be able to mitigate disease severity through early targeting of cells affected by virus-induced senescence.”

The team used animal models to study the effects of four distinct drugs which attack senescent cells in a targeted manner: navitoclax, fisetin, quercetin and dasatinib. Two of these senolytics are plant-based compounds; the other two are approved as or tested for cancer therapy. When used in hamsters and mice, all four substances – some used on their own, others in combination – achieved varying degrees of success in normalizing the hyperinflammation cascade and mitigating lung injury. The research team was able to refer to data from two smaller clinical studies which had already been completed. A combined analysis of the available data suggested that one of the senolytics tested was also able to reduce the risk of severe COVID-19 in humans.

“These results are extremely encouraging,” says Prof. Schmitt, who also conducts research at the German Cancer Consortium (DKTK). He adds: “Just like other therapeutic agents, however, senolytics can have side effects. Many questions therefore remain to be answered before we can consider them as a potential treatment against COVID-19. For instance: what is the effective dose? At which point and for how long will these substances need to be administered? What side effects are associated with their use? Might older people derive more benefit from senolytics than younger patients? After all, aging is associated with an increase in the number of cells which are ready to enter senescence. This needs to be explored in further clinical studies, some of which are already underway in a number of institutions across the globe.”

While the researchers await the results of these clinical COVID-19 studies with great interest, they are also looking beyond the current pandemic. “Our study has shown that different types of cells initiate senescence not only in response to an infection with SARS-CoV-2, but also in response to other viruses,” explains Dr. Lee. “Our hope is therefore that our findings will be of relevance to other infectious diseases in which the body’s immune response plays a crucial role in determining disease severity.”


*Lee S, Yong Y et al., Virus-induced senescence is driver and therapeutic target in COVID-19. Nature (2021), doi: 10.1038/s41586-021-03995-1



Original article

Molecular Cancer Research Center (MKFZ)

Department of Hematology, Oncology and Cancer Immunology (CVK)

Schmitt Lab at the MDC

Coronavirus research at the MDC

Johannes Kepler University Linz (JKU Linz)

Kepler University Hospital




Prof. Dr. Clemens Schmitt
Director of the Molecular Cancer Research Center (MKFZ)
Department of Hematology, Oncology and Cancer Immunology
Campus Virchow-Klinikum
Charité – Universitätsmedizin Berlin                  
Tel: +49 30 450 553 292

Back to Overview